ImmVirX and Innovent Enter into Clinical Trial Collaboration to Investigate the Combination of IVX037 and Sintilimab in Difficult-to-treat Cancers

ImmVirX’s Oncolytic Virus IVX037 to be assessed in combination with Innovent’s checkpoint inhibitor TYVYT® in Colorectal, Ovarian and Gastric Cancer to Investigate the Combination of IVX037 and Sintilimab in Difficult-to-treat Cancers Melbourne, Australia 21st February 2024 – ImmVirX Pty Limited, a life sciences company dedicated to pioneering the next generation of receptor-targeted immunotherapies for patients […]

ImmVirX receives $3.77M R&D tax refund for FY23

R and D

Melbourne, Australia 12 February 2024 – ImmVirX Pty Limited, a life sciences company focused on developing next-generation, receptor targeted oncolytic viral immunotherapies to transform outcomes for patients with some of the most prevalent and challenging cancer types, has received a $3,771,296 Research and Development (R&D) tax refund as part of the Australian Federal Government’s R&D […]

ImmVirX presents on its Phase 1a Clinical Study at Society for Immunotherapy of Cancer (SITC) Annual Meeting

Strong recruitment – commenced April 2023, 8 patients to date. Strong clinician interest across multiple sites.  Intralesional administration well tolerated, no dose-limiting toxicities.  Early signs of induction of potentially beneficial inflammatory cytokines/chemokines, such as CXCL10. Phase 1b combination with checkpoint inhibitor to open in early 2024. Melbourne, Australia 6 November 2023 – ImmVirX Pty Limited, a life […]

ImmVirX reports on operations for FY23

ImmVirX Operations 23

Melbourne, Australia 21 September 2023 – ImmVirX Pty Limited, a life sciences company dedicated to pioneering the next wave of receptor-targeted oncolytic viral immunotherapies for patients confronted with common yet formidable cancers, presents a summary of its operations for the financial year ending 30 June 2023. The year was headlined by the progress of IVX037, ImmVirX’s […]

ImmVirX raising $25m led by renowned healthcare VC OneVentures

One Ventures

– Up to A$25 million to be raised in Series B Financing, funding ImmVirX through to 2026 – Leading healthcare venture capital investor OneVentures subscribing for A$15 million – Up to $10 million to be raised from existing shareholders and placement of any shortfall – Dr Jeannie Joughin, a Principal at OneVentures, to join ImmVirX […]

ImmVirX enters the clinic with next generation oncolytic virus

First patient on trial in colorectal, gastric and ovarian cancer study (CP-IVX001) Melbourne, Australia 11 April 2023 – ImmVirX Pty Limited, a clinical stage oncology company focused on developing next-generation, receptor targeted oncolytic viral immunotherapies to transform outcomes for patients with some of the most prevalent and challenging cancer types, today announced that the first patient […]

ImmVirX receives $2.81M R&D tax refund for FY22

R and D

ImmVirX receives $2.81M R&D tax refund for FY22 Melbourne, Australia 28 November 2022 – ImmVirX Pty Limited, a life sciences company focused on developing next-generation, receptor targeted oncolytic viral immunotherapies to transform outcomes for patients with some of the most prevalent and challenging cancer types, has received a $2,813,837 Research and Development (R&D) tax refund […]

ImmVirX reports on operations for FY22

Immvirx review

Melbourne, Australia 26 September 2022 – ImmVirX Pty Limited, a life sciences company focused on developing next-generation, receptor targeted oncolytic viral immunotherapies to transform outcomes for patients with some of the most prevalent and challenging cancer types, is pleased to report on its operations for the year ending 30 June 2022. The year has seen […]

ImmVirX receives $858,183 R&D tax refund

R and D

Melbourne, Australia 4 March 2022 – ImmVirX Pty Limited, a life sciences company focused on developing next-generation, receptor targeted oncolytic viral immunotherapies to transform outcomes for patients with some of the most prevalent and challenging cancer types, today announced that it has received a $858,183 Research and Development (R&D) tax refund as part of the […]